Unexpected Diversity of Cellular Immune Responses against Nef and Vif in HIV-1-Infected Patients Who Spontaneously Control Viral Replication by Tarosso, Leandro F. et al.
Unexpected Diversity of Cellular Immune Responses
against Nef and Vif in HIV-1-Infected Patients Who
Spontaneously Control Viral Replication
Leandro F. Tarosso1, Mariana M. Sauer2, Sabri Sanabani3, Maria Teresa Giret2, Helena I. Tomiyama2,
John Sidney4, Shari M. Piaskowski5, Ricardo S. Diaz2, Ester C. Sabino3, Alessandro Sette4, Jorge
Kalil-Filho1, David I. Watkins5, Esper G. Kallas1,2*
1Clinical Immunology and Allergy Division, University of Sao Paulo, Sao Paulo, Brazil, 2Division of Infectious Diseases, Federal University of Sao Paulo, Sao Paulo, Brazil,
3 Sao Paulo Blood Bank, Sao Paulo, Brazil, 4 La Jolla Institute for Allergy and Immunology, La Jolla, California, United States of America, 5Department of Pathology,
Medical School, University of Wisconsin-Madison, Madison, Wisconsin, United States of America
Abstract
Background: HIV-1-infected individuals who spontaneously control viral replication represent an example of successful
containment of the AIDS virus. Understanding the anti-viral immune responses in these individuals may help in vaccine
design. However, immune responses against HIV-1 are normally analyzed using HIV-1 consensus B 15-mers that overlap by
11 amino acids. Unfortunately, this method may underestimate the real breadth of the cellular immune responses against
the autologous sequence of the infecting virus.
Methodology and Principal Findings: Here we compared cellular immune responses against nef and vif-encoded
consensus B 15-mer peptides to responses against HLA class I-predicted minimal optimal epitopes from consensus B and
autologous sequences in six patients who have controlled HIV-1 replication. Interestingly, our analysis revealed that three of
our patients had broader cellular immune responses against HLA class I-predicted minimal optimal epitopes from either
autologous viruses or from the HIV-1 consensus B sequence, when compared to responses against the 15-mer HIV-1 type B
consensus peptides.
Conclusion and Significance: This suggests that the cellular immune responses against HIV-1 in controller patients may be
broader than we had previously anticipated.
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Introduction
The majority of HIV-1-infected patients progresses to AIDS
within 10 to 15 years of infection if they are not treated with
antiretroviral drugs. Interestingly, a rare group of individuals
remains asymptomatic and has plasma viral loads at low or even
undetectable levels. They also maintain high CD4+ T cell counts
[1,2,3,4]. The complete understanding of why they are able to
control viral replication remains elusive. Several studies have
demonstrated that some individuals have been infected by
replication-incompetent viruses, which have unusual polymor-
phisms in nef [5,6], vpr [7], and other genes [8]. Vigorous CD4+
[9] and CD8+ T cell [10] responses against the virus have also
been detected in some controllers. These immune responses are
thought to be pivotal in the beneficial outcome and may be
actively containing viral replication [11,12].
Two early studies have suggested that the HIV-1-specific
cytotoxic T lymphocyte (CTL)-mediated response is a major
component associated with the control of replication following
primary infection [13,14]. These studies have shown that
reduction in HIV-1 viremia during acute infection is associated
with the appearance of HIV-1-specific CD8+ T lymphocytes and
that the absence of such responses is associated with prolonged
symptoms, persistent viremia and antigenemia, and a low CD4+ T
cell count. Some HLA alleles, including HLA-B*57 and HLA-
B*27, are consistently overrepresented in controllers [15,16],
further suggesting an important role of HLA class-I-restricted
CD8+ T cells in these individuals [17].
To characterize CD8+ T cell responses in controllers, peptide
scans with HIV-1 consensus B overlapping 15-mer peptides
encompassing the viral proteome have been performed [18,19,20].
Unfortunately, this method may underestimate the real breadth of
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the cellular immune responses against the autologous sequence of
the infecting virus, since CD8+ T cells recognize epitopes of eight
to 11 amino acids in length and the infecting virus sequence is
usually significantly different from consensus sequences.
Vif- and Nef-specific CTLs were shown to emerge in elite
controller SIV-infected rhesus monkeys after CD8 antibody-
mediated depletion and to be actively involved in the control of
SIVmac239 replication [21]. There is extensive amino acid
conservation in the Vif sequences, suggesting functional con-
straints. Indeed, an HIV-1 mutagenesis study demonstrated that
Vif mutants exhibited 25% reduction in a single round of
infectivity [22]. Furthermore, Vif is enriched for otherwise rare
tryptophans, which often are primary binding anchor residues of
several MHC class I molecules, including those associated with
slow progression to AIDS [15,23,24]. Therefore, boosting CTL
responses against Vif and Nef may be an especially potent
mechanism of viral suppression and these proteins may have
epitopes important for vaccine-induced immunity. Peptide scans of
CD8+ T cell-mediated immune responses throughout the Vif
consensus B sequence have already been performed identifying 18
epitopes, restricted by five HLA-A and nine HLA-B molecules
[25].
Here, we compared cellular immune responses against vif and
nef-encoded consensus B 15-mer peptides to responses against
HLA class I-predicted minimal optimal epitopes from consensus B
and autologous sequences in six patients who have controlled
HIV-1 replication without undergoing antiretroviral therapy.
Interestingly, this analysis revealed that three of our patients had
broader cellular immune responses against the minimal optimal
epitopes than against the 15-mer HIV-1 type B consensus peptide
set in ELISPOT-IFN-c assays. This peptide predicting approach
was more sensitive than conventional assays using consensus B
peptides and suggests that the cellular immune responses against
HIV-1 epitopes may be broader than had been previously
anticipated.
Methods
Ethics Statement
Informed written consent was obtained from all the patients and
the study was approved by the Ethics Committees of the Federal
University of Sao Paulo [# 0041/08], University of Sao Paulo [#
4537], and by the Comissa˜o Nacional de E´tica em Pesquisa [#
14781].
Subjects
Blood samples were collected from six male subjects participat-
ing in our cohort of recently HIV-1 infected patients [26]. Patients
were considered as recently HIV-1-infected when at least one
positive HIV-1 ELISA test was confirmed with a Western Blot
assay, but was negative using the less sensitive HIV-1 ELISA test
Vironostika HIV-1 micro-ELISA system, BioMe´rieux, Durham,
NC. The six patients were classified as controllers of viral
replication since most of their plasma HIV-1 RNA loads were
below 1,000 copies/mL without antiretroviral therapy.
CD4+ T cell counts and Viral Load (VL) quantification
Peripheral blood absolute CD4+ T cell counts were assessed
using the BD Tritest anti-CD4-FITC/anti-CD8-PE/anti-CD3-
PerCP monoclonal antibody (mAb) cocktail and BD TruCount
Tubes (BD Biosciences, San Diego, CA), according to the
manufacturer’s instruction, using a FACSCalibur flow cytometer
(BD Biosciences). Plasma HIV-1-RNA was quantified by a
standardized reverse transcriptase PCR assay (Amplicor HIV-1
Monitor; Roche Diagnostic Systems, Indianapolis, IN) until
January 2007, and subsequently replaced by the branched DNA
assay (VersantH - bDNA HIV-1 RNA 3.0 ASSAY, Bayer Health
Care LLC Tarrytown, NY).
HLA class I typing
Subjects were typed with intermediate resolution for major
histocompatibility complex (MHC) class I antigen expression using
sequence-specific primer PCR kits (Pel-Freez SSP UniTray;
Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions.
HIV-1 vif and nef sequencing
The full-length HIV-1 proviral genome was amplified by
nested-PCR in five overlapping fragments of 1.8 to 3.0 kb each
and sequenced on an automated sequencer (ABI 3130; Applied
Biosystems Inc., Foster City, CA) as previously described [27]. The
data from sequenced fragments were edited and assembled into
contiguous sequence by the Sequencher program 4.0 (Gene Code
Corp., Ann Arbor, MI). The vif and nef sequences were aligned
with the references using the ClustalX 1.81 program, and further
hand edited [28]. Phylogenetic trees were created by the
maximum likelihood (ML) methods implemented in the program
PHYML [29] using the GTR+I+G substitution model and a
BIONJ starting tree. A heuristic search for likelihood was
performed using the SPR branch-swapping algorithm. Divergence
of amino acid substitutions per site within the Vif and Nef
sequences was calculated using the Poisson correction method in
Mega version 4.0 software.
HLA class I-restricted epitope prediction and synthesis
We utilized a consensus prediction approach [30], based on the
use of several available prediction methods including ARB
(average relative binding), SMM (stabilized matrix method) and
ANN (artificial neural network) algorithms available through the
IEDB (Immune Epitope Database). We also utilized some matrix
methods available at NetMHC, and our own PSCL (positional
scanning combinatorial library) matrices. ARB, SMM, and ANN
predict the quantitative binding affinity. The ANN is a nonlinear
model, and ARB and SMM generate scoring matrices [31,32].
The HIV-1 Vif and Nef consensus B and the autologous amino
acid sequences were scanned to identify potential HLA class I
binding peptides between nine and 10 residues in length. All
possible peptides were scored and ranked for each allele in the
donor population using corresponding algorithms. When more
than one method was available for a specific allele, the peptides
were ranked on the basis of the median score. When an algorithm
was not available for a specific allele, predictions were based on an
algorithm for another allele in the same allele family, or an allele
within the same HLA super type. Candidate peptide sequences
ranked in the top 2.5% for each allele were chosen for synthesis.
The peptides were then synthesized as crude material. Lyophilized
material was resuspended at 20 mg/mL in 100% dimethyl
sulfoxide (DMSO) and then diluted to required concentrations
in 100% DMSO.
Interferon gamma (IFN-c) enzyme-linked immunospot
(ELISPOT) assay
Two sets of ELISPOT assays were carried out. In the first set,
15-mer peptides overlapping by 11 amino acids corresponding to
HIV-1 consensus B Vif and Nef (NIH AIDS Research and
Reagent Program, Rockville, MD) were used at a final
concentration of 10 mg/mL. In the second set of ELISPOT
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assays, HLA class I-restricted Vif and Nef peptides of nine or 10
amino acids in length (predicted as described above) were used at
the same concentration. For each patient, the number of HLA-
restricted peptides tested ranged from 70 to 110. Out of these
peptides, some were consensus B-based and others were
autologous sequences-based (See supporting information Table
S1: Number of peptides tested for each patient in the ELISPOT
assays). Briefly, 96-well flat-bottomed nitrocellulose plates (Multi-
screen, Millipore, Bedford, MA) were coated with 0.5 mg of anti-
IFN-c mAb (Mabtech, Nacka, Sweden) for a 1 h incubation at
4uC. Plates were washed three times with 1xPBS and then 16105
PBMC resuspended in RPMI 1640 supplemented with penicillin,
streptomycin, and 10% fetal bovine serum (R10) were added to
the wells. The R10 also contained each Vif or Nef peptide,
Concanavalin-A (positive control), or only 2.0 mL of 100% DMSO
with no peptide (negative control). Plates were incubated for 16 h
at 37uC in 5% CO2, after which the cells were discarded. After
washing the plates five times with 1xPBST (1xPBS containing
0.05% Tween 20), 0.05 mg of biotinylated anti-IFN-c mAb
(Mabtech) was added and the plates were incubated for further
2 h at room temperature. Following additional five washes with
1xPBST, 0.07 mg per well of alkaline phosphatase (Vector
Laboratories Inc., Burlingane, CA) in 50 mL of 1xPBS were
added for 1 h at room temperature. After another set of five
washes with 1xPBST, 50 mL of BCIP/NBT (5-Bromo-4-Chloro-3-
Indolyl Phosphate/Nitro Blue Tetrazolium) substrate solution
(Sigma-Aldrich, St Louis, MO) per well were added, and the plates
were developed for about 30 min. Spots were counted using either
an automated stereomicroscope (KS ELISPOT, Zeiss, Oberko-
chem, Germany) or AID reader (AID, Germany). HIV-1-specific
responses were reported as the number of spot-forming units
(SFU)/16106 PBMC after subtraction of the background IFN-c
secretion. A response was considered positive if the number of
SFU exceeded 55 SFU/16106 cells and was at least four-times the
level of the wells with no peptide [33] (See supporting information
Figure S1: ELISPOT assays using 15-mer consensus B peptides
and HLA-restricted minimal optimal peptides).
Results
In the present study, we examined cellular immune responses in
six HIV-1-infected subjects who controlled viral replication. All of
them had documented infection for at least three years, with a
mean duration of four years. We used ELISPOT-IFN-c assays
with 15-mers overlapping by 11 amino acids encompassing the
entire length of the Vif and Nef consensus B sequences and HLA
class I-restricted minimal optimal Vif- and Nef-epitopes synthe-
sized from consensus B and autologous virus sequences.
CD4+ T cell counts and VL quantification
The six controller patients were infected through unprotected
homosexual activity and have been followed-up since diagnosis in
the early stage of the infection. HIV-1 RNA levels in the plasma
and peripheral CD4+ T cell counts were determined approxi-
mately every three months for at least 1,200 days. The majority of
VL quantifications was below 1,000 copies/mL for all the patients
and the mean CD4+ T cell count was 642 cells/mL varying from
353 to 1097 cells/mL (Table 1). Only two individuals (1068 and
1022) had occasional viral loads above 2,000 copies/mL during
their more recent follow-up. Patient 1098 had occasional viral
loads above 1,000 copies/mL. Patients 1073, 1103, and 2017
presented all viral loads below the detection limits (Supporting
information Figure S2: Viral load in the controller patients). No
patient was homozygous for the CCR5D32 polymorphism, and
only patient 1068 was heterozygous for this deletion. We also
looked for active GBV-C infection in our patients, and none of
them tested positive for virus RNA.
The HLA-B*57 allele was overrepresented in subjects who
controlled viral replication
We typed 157 individuals from our cohort of HIV-1 recently
infected patients for their HLA class I alleles. Among the six
controllers, three out of them were positive for the HLA-B*57
allele (Table 1), which has been associated with restriction of HIV-
1 replication [1,15]. The overall frequency of individuals positive
for the HLA-B*57 allele in the entire cohort was 5% (eight out of
157 patients).
Characterization of the HIV-1 genome and genetic
diversity
Phylogenetic analysis of the nucleotide sequences of vif and nef
regions showed that all six controller patients were infected with
subtype B strains. The segregation patterns of vif and nef sequences
were randomly distributed among subtype B reference sequences
and other non-controller patients’ sequences without apparent
clustering (Figure 1). All of the controller patients had an intact
genomic organization with open reading frames. No gross
insertion or deletion was observed in both vif and nef regions. In
our six controller patients, the HIV-1 vif and nef autologous
sequences differed from the HIV-1 consensus B sequences by an
average value of 15.1% and 13.6%, respectively. The overall mean
amino acid distances of the six controllers’ sequences compared to
consensus B sequences from the reported positive Vif and Nef
epitopes were 19.4% (range; 9.7%–28.3%), and 18.1% (range;
10.8%–25.4%), respectively.
Table 1. HLA type and clinical characteristics of study patients.
Patient ID HLA
Highest VL
(copies/mL)
CD4+ T cell count
range (cells/mL)
Follow-up
(days)
A locus alleles B locus alleles
1022 02 02 14 52 2,090 384–819 2063
1068 03 29 70 58 7,260 721–1035 1546
1073 01 34 35 57 ,400 433–762 1498
1098 03 26 27 57 807 654–882 1169
1103 01 02 35 57 ,400 601–909 1162
2017 02 11 39 53 ,400 518–1030 1904
doi:10.1371/journal.pone.0011436.t001
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HLA-class I-restricted epitope prediction
CD8+ T cells preferentially recognize MHC class I-bound
peptides of eight to 11 amino acids in length. T cell responses
against consensus B 15-mer peptides might, therefore, not fully
capture the complexity of T cell recognition of epitopes in vivo. To
address this issue, we scanned full-length amino acid sequences of
the Vif and Nef proteins predicted from autologous viruses. For a
comparison sake, we also scanned consensus B peptides using the
same HLA class I algorithms. We identified 558 optimal, HLA-
restricted 9- or 10-mer peptides (70 to 110 per patient) that were
predicted to bind to the HLA-class I A and B molecules of the
patients (Supporting information Table S1). After synthesis, these
558 peptides were used individually in ELISPOT-IFN-c assays.
Cellular immune responses detected against 15-mer
consensus B peptides
Five of our six patients recognized Nef epitopes and two of them
recognized Vif epitopes using ELISPOT assays with the consensus
B 15-mer peptides. Of the 49 peptides that span the Nef sequence
(205 amino acids in length), five were reactive. Four 15-mers of the
46 spanning the entire Vif sequence (191 amino acids in length)
induced significant production of IFN-c in the ELISPOT assays
(Supporting information Table S2, Figure 2). The region between
amino acids 61 and 95 of the Nef consensus B sequence contained
more T cell epitopes than any other region; six of the eight positive
responses were located in this region. However, similar epitope
concentrations were not observed in Vif (Supporting information
Table S2, Figure 2).
HLA class I-restricted minimal optimal epitopes revealed
a broader immune response than 15-mer consensus B
peptides
T cells from three controller patients recognized additional
epitopes when ELISPOT assays were carried out with the minimal
optimal epitopes, compared to the assays using the consensus B
15-mers. For the Nef HLA class I-restricted epitopes, 22 positive
responses were detected (Supporting information Table S2,
Figure 2A). For the Vif HLA class I-restricted peptides, there
were 16 IFN-c responses (Supporting information Table S2,
Figure 2B). We found positive responses to peptides restricted to
eight HLA class I molecules. The majority of these responses was
restricted by B locus alleles (74%) and was directed against Nef
epitopes (63%).
Like the 15-mer consensus B peptides spanning Nef, T cells
recognized minimal optimal epitopes concentrated in the area
between amino acids 61 and 95. In this region, we detected seven
of the 22 responses found. Interestingly, we observed an additional
concentration of T cell responses against minimal optimals in the
first 20 amino acids of Nef (Figure 2A). Six positive responses were
detected in this region. By contrast, analyses of the HLA-restricted
responses against Vif did not reveal any epitope rich region
(Figure 2B).
Figure 1. Maximum likelihood phylogenetic trees. Trees of nef (A) and vif (B) sequences from six controller patients (black circles) along with
references for all known subtypes from the LANL database (labeled branches) are displayed. HXB2_LAI_IIIB_BRU (K03455) HXB2 reference sequence is
boxed. The construction of the trees is described in the text. For purposes of clarity, the trees were midpoint rooted. The aLRT values of $70% are
indicated at nodes. The scale bars represent 0.05 nucleotide substitution per site. Clustering of the six controllers with subtype B is evident in nef and
vif trees (aLRT $85%).
doi:10.1371/journal.pone.0011436.g001
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We identified three regions (two in Nef and one in Vif) where
15-mers peptides (Figure 2, yellow arrows) elicited positive
responses not seen after minimal optimal peptides stimulation
(Figure 2, green and red arrows). Specifically, the Nef WY15
peptide was recognized by patients 1103 and 1098 and the QP15
peptide by patient 2017. The Vif VG15 peptide and the CY15
peptide were recognized by patient 2017. No minimal optimal
peptides were predicted in these regions by the employed
bioinformatics tools using the autologous and consensus B
sequences. Recognition of these 15-mers was a relatively rare
event when compared to the large number of HLA-predicted
epitopes that were recognized.
We detected more T cell responses against Vif and Nef when we
used HLA class I-restricted minimal optimal epitopes than when
we used the conventional approach of testing consensus B 15-mers
(Figure 3A and 3B, respectively). Indeed two aspects of T cell
recognition were shown to be higher using this approach: the
number of epitopes eliciting positive responses and the total
number of SFU detected in the assays (Figure 3C and 3D,
respectively).
We also compared the ability of PBMC from our six patients to
recognize consensus B 15-mers, HLA-restricted minimal optimal
epitopes in the consensus B sequence and HLA-restricted minimal
optimal epitopes in the autologous HIV-1 sequences. Reactivity
was higher (in terms of frequency and the number of epitopes
recognized) using the HLA-restricted minimal optimal epitopes in
the consensus B and autologous virus. Indeed, when we used either
consensus B or autologous sequence to synthesize HLA-restricted
Figure 3. Cellular immune responses against consensus B-based and autologous-based Vif and Nef peptides. Stacked bars show results
of the ELISPOT assays for each of the six controller patients for Vif (A) and Nef (B). Each portion of the bar indicates one peptide and its height represents
the amount of spots shown in the assays. The left black/gray bar for each patient shows positive spots detected with 15-mer peptides based on the
consensus B sequence (15-mer/ConsB) and right colored bar shows positive spots detected with minimal optimal HLA-restricted peptides (HLA-restr.). C.
Reactivity of PBMC in the ELISPOT assays to consensus B 15-mers and HLA-restricted minimal optimal epitopes from consensus B and autologous
sequences in terms of number of recognized epitopes. D. The magnitude of the response in spot forming units per 106 cells.
doi:10.1371/journal.pone.0011436.g003
Figure 2. Alignments of the viral sequences and maps of the cellular immune responses. Alignments and maps of immune response from
six HIV controller patients to consensus B sequence and maps of the cellular immune responses detected in the ELISPOT assays. The arrows represent
the peptides, which elicited positive IFN-c responses. Yellow arrows show responses against consensus B 15-mers, green arrows show responses
against consensus B minimal optimal HLA-restricted peptides, and red arrows show responses against autologous sequences minimal optimal HLA-
restricted peptides. A. First sequence is the map of immune response against consensus B 15-mer peptides for Nef. Other sequences show the maps
of immune responses detected against minimal optimal epitopes from consensus B and autologous sequences. B. Vif sequences, see Fig. 2A legend
for explanation.
doi:10.1371/journal.pone.0011436.g002
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minimal optimal epitopes, a higher number of positive responses
were identified. For Vif, three out of the six controllers had
increased positive responses against HLA-restricted minimal
optimals while two patients remained without detectable responses
(Figure 3A). For Nef, three out of the six patients had a higher
number of positive responses against HLA-restricted peptides, and
one patient remained without detectable responses (Figure 3B).
Interestingly, the consensus B HLA-restricted minimal optimal
epitopes proved to be more sensitive in the detection of Vif-specific
responses, whereas the autologous HLA-restricted minimal
optimal epitopes were more sensitive for the detection of Nef-
specific responses (Supporting Information Table S2, Figure 3C
and 3D).
Discussion
HIV-1 controllers, although rare, represent about 1% of HIV-1-
infected individuals [34]. The controller patients studied here have
been monitored for at least three years since early infection.
Overall, they have had CD4+ T cell counts (mean number during
all follow-up visits of 642 cells/mm3) and plasma viral loads
(,2,000 copies/mL) similar to other previously reported cohorts
of controller patients [3,34,35]. In this study, we demonstrated
that assessing T cell responses in subjects who successfully control
viral replication with consensus B 15-mer peptides may be less
sensitive when compared to HLA-restricted minimal optimal
epitopes. Indeed, by HLA-restricted minimal optimals, we have
discovered broad Vif and Nef-specific T cell responses in our
patients.
As viral load relates to transmission and disease progression
[36,37], further comprehension of the mechanisms by which some
infected individuals spontaneously control HIV-1 replication could
assist in the development of vaccines that augment control of
infection, reduce risk of transmission, and ameliorate disease
progression [35,38]. It is, therefore, critical to clearly define
protective cellular immune responses in HIV-1-infected subjects
who successfully control viral replication and then to engender
these responses by vaccination.
Some HLA class I alleles can influence disease outcome,
including control of viremia [3,15,23,34]. Overrepresentation of
HLA-B*57 (approx. 85%) was found in HIV-1 controllers in
several studies [1,3,15]. Not surprisingly, we found the same allele
enrichment in our controller patients since three out of the six
patients expressed HLA-B*57. In our entire cohort of recently
HIV-1 infected individuals, the frequency of individuals carrying
this allele was less than 5%. Despite the strong association with
viral control, it is unclear whether HLA-B*57 mediates its effects
entirely via HIV-1-specific CD8+ T cell responses or by other
mechanisms. It has been reported that carriers of this allele often
mount a potent T cell response against one or more highly
conserved viral epitopes, but viral escape from these responses is
not always associated with viral rebound [39]. Also, it is well
known that some individuals control viral replication without
carrying ‘‘protective’’ HLA alleles [1].
An auxiliary gene of primate immunodeficiency viruses, vif is
required for HIV-1 replication in lymphocytes and macrophages
[40,41,42] and is consequently maintained intact in vivo in infected
people [43]. Vif was recently found to counteract the host antiviral
factors APOBEC3G and APOBEC3F by binding to them and
promoting their degradation. Hassaı¨ne et al. [44] found that the
precise amino acid signature Ser132Arg in Vif correlated with a
five-fold reduction in replication in long term nonprogressor.
Interestingly, sequencing of the vif gene showed that only patient
1022 had a virus carrying this mutation (Figure 2B). By contrast,
the very conserved 144SLAQXLA149 residue, known to be one of
the binding sites for APOBEC [45] was invariant in the six
controllers described here.
The importance of Nef in the pathogenesis of HIV-1 was
investigated after transmission of the virus from an HIV-1-infected
blood donor to six recipients. Their CD4+ T cell counts have been
stable and normal for 10 to 14 years after transfusion. Their virus
sequences showed similar deletions in the nef gene. In our study,
we found no marker in the nef sequence that could explain the
transmission of an attenuated virus to our patients. Phylogenetic
analysis of nef and vif sequences (Figures 1A and 1B, respectively)
revealed that the viral genes from the controller subjects inter
digitated with sequences from other recently HIV-1-infected non-
controller individuals, without apparent clustering. Our observa-
tions agree with some results from a single codon-level comparison
of all coding HIV-1 genes among 95 elite controllers and persons
with progressive infection. This study indicated that the ability to
spontaneously control of HIV-1 replication was not attributed to
either specific viral genetic polymorphism or gross viral genetic
defects [46].
Natural history studies in cohorts of HIV-1-infected humans
and analogous SIV studies in macaques showed that cell-mediated
immunity can control primate immunodeficiency virus replication
[34]. Friedrich et al. [21] examined Indian-origin rhesus macaques
presenting robust and durable control of SIVmac239 viremia
during chronic infection. By depleting CD8+ lymphocytes from
these animals, they discovered that Nef- and Vif-specific CD8+ T
cell responses along with robust Gag-specific CD4+ T cell
responses were responsible for the control of the SIVmac239
replication. While Nef and Gag have been used in vaccine
development, Vif has not been used as a vaccine immunogen to
date. Therefore, it is possible that boosting CTL responses against
Vif may be an especially potent mechanism of suppressing viral
replication.
To determine a method to assess CD8+ T cell responses to
HIV-1 by measuring intracellular cytokine production, Betts et al.
[47] compared responses to HIV-1 Gag 15-mers overlapping by
11 amino acids to responses elicited by optimized epitopes of eight
to 11 amino acids in length and observed a marked difference in
reactivity. They hypothesized that the overlapping 15-mers panels
may underestimate the total HIV-1-specific response. This could
be explained by a number of factors such as the location of the
recognized sequence within the 15-mer, the effects of amino acid
overlaps, and potential sequence differences between peptides and
autologous virus. In fact, in our study population, the HIV-1 vif
and nef autologous sequences differ from HIV-1 consensus B
sequences by an average value of 15.1% and 13.6%, respectively.
A previous study has evaluated the cellular immune response
against other proteins using autologous virus isolates. Altfeld et al.
[48] demonstrated the usefulness of autologous sequences to detect
immune responses against Tat and Vpr. They also suggested that
the entire immune response to the virus may be underestimated
using consensus sequence based peptides. However, this effect
could not be detected for Gag-specific responses, which could
reflect less structural changes in this protein compared to Tat and
Vpr.
In our study, some regions in Nef and Vif engendered positive
responses when we used 15-mers but not when we used HLA-
restricted minimal optimal peptides (e.g. the Nef peptide WY15
and the Vif peptide VG15, Figure 2). Since 15-mers peptides are
know to stimulate both CD4+ and CD8+ T cells [47], it is possible
that some of these 15-mer-specific responses were mediated by
CD4+ T cells or were restricted by HLA class I locus Cw
molecules. Thus, 15-mers can detect both CD4- and CD8-
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mediated T cell responses. Conversely, the HLA-class I restricted
minimal optimal epitopes are expected to stimulate only CD8 T
cells. One might, therefore, expect more responses against the 15-
mers. However, in our study, the HLA-restricted minimal optimal
epitopes engendered more responses than the 15-mers did,
suggesting that these minimal optimal epitopes are much better
at detecting CD8 T cell responses than the corresponding 15-mers.
The inability of the employed bioinformatics approach to predict
these particular epitopes and the possibility of escape could also
explain why some responses were detected with 15-mers but were
not detected using autologous HLA-restricted epitopes. We did
not, however, investigate whether these epitopes escaped by
sequencing the virus at a second time point.
Collectively, our data suggest that Nef and Vif-specific responses
may be broader than we had anticipated. HLA-restricted minimal
optimal peptides increased of our ability to detect positive cellular
responses against Nef and Vif. In conclusion, our study suggests
that selection of peptides based on an individual’s HLA class I
allele, either using autologous or consensus B sequences, may be
important in the definition of antigen-specific CD8+ T cell
responses. This is likely to be true not only in subjects who
successfully control viral replication but in any HIV-1-infected
individual.
Supporting Information
Table S1 Number of peptides tested for each patient in the
ELISPOT assays.
Found at: doi:10.1371/journal.pone.0011436.s001 (0.04 MB
DOC)
Table S2 Positive peptides in the ELISPOT assays. *per 106
cells; **Columns ‘‘Source’’ indicate whether the HLA-restricted
peptides were predicted from Consensus B (Cons) or autologous
sequences ([Patient ID]). In some cases, the Consensus B and the
autologous sequences are identical, so the source of the peptide is
indicated as Cons/[Patient ID].
Found at: doi:10.1371/journal.pone.0011436.s002 (0.01 MB
PDF)
Figure S1 ELISPOT assays using 15mer consensus B peptides
and HLA-restricted minimal optimal peptides. ELISPOT assays
were done as described in the Methods section using either Vif and
Nef 15mer consensus B peptides or Vif and Nef HLA-restricted
minimal optimal peptides. For both assays, a concentration of
10 mg/mL for each peptide tested separately was used. A response
was considered positive if the number of SFU exceeded 55 SFU
per 106 cells and was at least four-times the level of the wells with
no peptide.
Found at: doi:10.1371/journal.pone.0011436.s003 (4.11 MB
TIF)
Figure S2 Viral load in the controller patients. Quantifications
of viral load were performed by RT-PCR or branched DNA
assays. The graph shows the values using a log scale.
Found at: doi:10.1371/journal.pone.0011436.s004 (6.22 MB TIF)
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